Table 2.

Results for atorvastatin vs. pravastatin trial (PROVE-IT).

	The PROVE-IT Trial Cannon et al.41				Columbia University Irving Medical Center (CUIMC)
Baseline charactertics	Pravastatin	Atorvastatin	Pooled		Indication only		With eligibility criteria
	n = 2063	n = 2099	n = 4162	σ	n = 3972	ΔRCT	n = 3180	ΔRCT
Age	58.3	58.1	58.20	11.25	60.37	0.137	59.95	0.111
Sex
Male	1617	1634	78.11%		45.92%	−0.322	45.88%	−0.323
Female	445	465	21.89%		54.08%	0.322	54.09%	0.323
Unknown			0.00%		0.03%	0.000	0.03%	0.000
Race
White	1865	1911	90.73%		28.23%	−0.611	71.42%	−0.604
Other	198	188	9.27%		71.77%	0.611	28.58%	0.604
Diabetes	361	373	17.64%		29.82%		26.57%
Hypertension	1014	1077	50.24%		60.72%	0.105	57.64%	0.074
Current smoker	766	763	36.74%		4.48%	−0.323	4.18%	−0.326
Prior MI	395	374	18.48%		34.42%	0.159	34.40%	0.159
PCI
Prior to index event	320	322	15.43%		10.31%	−0.048	10.31%	−0.051
After index event	1426	1442	68.91%		15.30%	−0.536	15.16%	−0.538
Coronary bypass surgery	221	233	10.91%		4.00%	−0.069	1.38%	−0.095
Peripheral artery disease	136	105	5.79%		15.17%	0.094	13.33%	0.075
Prior statin therapy	514	535	25.20%		42.73%	0.175	37.30%	0.121
Index event
Unstable angina	614	604	29.26%		48.47%	0.192	50.88%	0.046
MI without ST segment elevation (NSTEMI)	757	747	36.14%		19.80%	−0.163	15.22%	−0.209
MI with ST segment elevation (STEMI)	690	748	34.55%		31.73%	−0.028	33.90%	0.163
Median lipid values
Total cholesterol	180	181	180.50	–	171.67	−0.151	169.54	−0.194
LDL cholesterol	106	106	106.00	–	100.41	−0.110	99.18	−0.138
HDL cholesterol	39	38	38.50	–	45.07	0.364	45.06	0.370
Triglycerides	154	158	156.02	–	141.95	−0.110	137.95	−0.145